Clinical Trials Browser

Phase 1/2 × Terminated × tepotinib × Clear all

NCT04739358 2023-10-18

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Phase 1/2 Terminated

Carcinoma, Non-Small-Cell Lung